Pomalidomide (Pomalyst) — Coverage Criteria
Defines coverage and authorization criteria for pomalidomide (Pomalyst) for FDA-approved and compendial oncology indications for members of Neighborhood Health Plan of Rhode Island when approval criteria are met.
No material clinical or coverage changes in this revision.
Coverage and Medical Necessity Criteria
Initial and indication-specific coverage criteria
Covered when ALL of the following are met for multiple myeloma (initial authorization up to 12 months):
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.